Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Oddity Tech shares jumped 23.8% in pre-market trading after the beauty and wellness technology company posted second-quarter 2026 adjusted EBITDA of $13 million, surpassing its own $8–$10 million guidance, and issued a materially improved outlook for the third quarter. Management highlighted shrinking revenue declines, stronger EBITDA guidance, siz…
Chime's agreement to buy Stride for $590 million and obtain a national bank charter sent its shares up 10% premarket. The acquisition, expected to close in the first half of 2027, is projected to deliver more than $100 million in net synergies and give Chime enhanced control over product development, lower funding costs and room to expand lending, …
Kratos is carving out a low-cost, high-volume niche in unmanned systems and national-security hardware. Recent Q2 beats and raised guidance show demand; the stock has been punished and sits near its 52-week low. This trade targets a mid-term rebound tied to contract conversion and backlog realization while respecting program and cash-flow risks.
J.Jill Inc. stock rallied sharply in pre-market trading after the company reported second-quarter fiscal 2026 results that beat Wall Street estimates on both earnings and revenue, raised its full-year outlook, and announced an added quarterly cash dividend. Management cited strategic progress and a meaningful benefit from tariff refunds that bolste…
Two months before the U.S. midterm elections, markets display an unusual mix of apparent calm and underlying vulnerability. Equities sit near record highs, volatility gauges have fallen toward 2026 lows, and cross-stock correlations are unusually low, suggesting independent moves across names. Yet a range of upcoming catalysts - from economic relea…
Gilat Satellite Networks announced that its subsidiary, Gilat DataPath, received an over $32 million order from the U.S. Department of War for multi-band Deployable Ku/Ka/X-band Earth Terminals (DKET) systems. These relocatable ground platforms support rapid deployment and resilience in mission-critical defense communications, reinforcing Gilat Def…
Bilibili Inc. has completed a $500 million offering of convertible senior notes due 2031, alongside a concurrent equity placement and share repurchases. The offering involved qualified institutional buyers outside the US, and Tencent subscribed to an additional $200 million in notes subject to shareholder approval. The company also repurchased shar…
Meta Platforms rallied in pre-market trade after the company launched Muse, an autonomous AI personal agent, and followed up a model upgrade with institutional buying by Pershing Square. The combined developments appear to have driven the stock higher despite broader market weakness, prompting investors to reconsider the monetization path for Meta'…
Melius Research says an extended shutdown at Saudi Arabia's Jizan petroleum and power complex is contributing to rising oil prices. The facility has been offline for six weeks and the firm notes the closure reduces refining capacity at a time when U.S. fuel inventories are low and Brent crude has climbed to about $98 per barrel.
Can-Fite BioPharma announced publication of a peer-reviewed case report detailing the successful treatment of a patient with advanced decompensated liver cirrhosis using their drug Namodenoson, resulting in resolution of ascites and regression of esophageal varices. The patient remained clinically stable for 28 months on treatment before undergoing…
OKYO Pharma Limited announced presentations at the Ophthalmology Futures European Forum and ESCRS iNovation Day, highlighting the advancement of its lead drug urcosimod in treating neuropathic corneal pain. The company also reported positive feedback from the FDA validating its regulatory pathway and a strengthened cash position, supporting the upc…
Cocrystal Pharma announced that the last subject has been dosed in its Phase 1b norovirus challenge study evaluating CDI-988 as a preventive and treatment for norovirus infections. This study is the first clinical trial of a direct-acting antiviral specifically targeting norovirus, aiming to address a significant unmet medical need. CDI-988 has sho…
Eledon Pharmaceuticals announced an upcoming oral presentation at the International Congress of The Transplantation Society showcasing long-term safety and efficacy data of its lead investigational drug, tegoprubart, for preventing kidney transplant rejection. The data come from the Phase 2 BESTOW trial and its extension, highlighting the drug's po…
Xanadu Quantum Technologies Limited has entered into a collaboration with ASML to develop advanced lithography techniques aimed at reducing optical losses in photonic quantum computing chips. This partnership seeks to address critical challenges in achieving fault-tolerant and error-corrected quantum hardware, accelerating progress toward utility-s…
INLIF LIMITED announced that its Extraordinary General Meeting of Shareholders originally scheduled for September 8, 2026, was adjourned due to insufficient shareholder attendance to meet quorum requirements. The meeting is set to reconvene on September 15, 2026. Previously submitted votes remain valid, and shareholders who have not yet voted are e…
Aya Gold & Silver released an updated 2026 Preliminary Economic Assessment for its Boumadine polymetallic project in Morocco, showing a more than doubling of the after-tax net present value to $3.5 billion and an internal rate of return of 93%. The project life extends to 14 years with improved payable metal production and capital efficiency. The u…
Satellos Bioscience announced that their lead oral small molecule drug candidate, previously known as SAT-3247, has been assigned the International Nonproprietary Name (INN) 'forazapadin.' The drug targets AAK1 to promote muscle regeneration and is currently in Phase 2 clinical trials for Duchenne muscular dystrophy (DMD), with plans to initiate a …
Kura Oncology has established Caspian Therapeutics, a separately financed subsidiary focused on advancing KO-7246, a next-generation menin inhibitor designed for diabetes and cardiometabolic diseases. Caspian raised $50 million led by BVF Partners and supported by key biotech investors including Eli Lilly. Preclinical studies show promising results…
Rezolute announced that the FDA review of their Phase 3 sunRIZE study data for their drug ersodetug in treating congenital hyperinsulinism (HI) is ongoing without a defined timeline. While the study did not meet its primary endpoint for statistical significance, secondary analyses indicate glycemic improvements. The open-label extension phase conti…
Pyxis Oncology reported positive updated results from its Phase 1 monotherapy study of micvotabart pelidotin (MICVO) in second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma (2L+ R/M HNSCC). The study showed a 36% confirmed objective response rate, 94% disease control rate, median progression-free survival of 6.2 months,…
Autolus Therapeutics announced that the FDA granted RMAT designation to its T cell therapy candidate obecabtagene autoleucel (obe-cel) for treating systemic lupus erythematosus (SLE) and lupus nephritis (LN), accelerating development and regulatory review. The company plans further clinical data presentations and continues enrollment in a pivotal P…
X4 Pharmaceuticals, a US-based biotech firm focused on rare hematology diseases, will take part in a management fireside chat at the 2026 Wells Fargo Healthcare Conference. The company is developing and commercializing mavorixafor, an oral CXCR4 antagonist currently approved in the US and undergoing pivotal Phase 3 trials for chronic neutropenia. T…
ODDITY Tech Ltd. reported Q2 2026 net revenue of $181 million, down 25% year-over-year, with adjusted EBITDA of $13 million and net income of $13 million. The company highlighted strong revenue growth in its SpoiledChild brand and promising early results from METHODIQ. It is addressing a technical advertising issue with its largest partner affectin…
Fractyl Health, a clinical-stage metabolic therapeutics company targeting obesity and type 2 diabetes, announced CEO Dr. Harith Rajagopalan will present and engage in meetings at the H.C. Wainwright and Morgan Stanley healthcare investment conferences in September 2026. The events will be webcast and focus on the company’s advanced metabolic diseas…
Balchem Corporation, a global specialty ingredient manufacturer serving health and nutrition markets, announced its participation in the 9th Annual Wells Fargo Consumer Conference. Senior executives including the CEO, CFO, and Senior Director of Investor Relations will present, highlighting the company's multi-segment operations across human nutrit…
